Table 1.
Baseline Characteristics of Patients
| Characteristic | Patients (n = 52) |
|---|---|
| Sex | |
| Male | 28 (54%) |
| Female | 24 (46%) |
| Age | |
| <65 | 32 (62%) |
| 65–75 | 10 (19%) |
| ≥75 | 10 (19%) |
| Smoking history | |
| Yes | 21 (40%) |
| No | 31 (60%) |
| ECOG PS | |
| ≤1 | 42 (81%) |
| 2 | 10 (19%) |
| Pathological type | |
| Adenocarcinoma | 38 (73%) |
| Squamous cell carcinoma | 14 (27%) |
| Gene status | |
| EGFR mutation | 26 (50%) |
| Wide type/unknown | 26 (50%) |
| Clinical stage | |
| III B | 10 (19%) |
| IV | 42 (81%) |
| Number of distant metastases | |
| ≤2 | 38 (73%) |
| >2 | 14 (27%) |
| Brain metastases | |
| Yes | 18 (35%) |
| No | 34 (65%) |
| Liver metastases | |
| Yes | 8 (15%) |
| No | 44 (85%) |
| Number of previous treatment lines | |
| ≤3 | 42 (81%) |
| >3 | 10 (19%) |
| Number of previous chemotherapy lines | |
| ≤2 | 40 (77%) |
| >2 | 12 (23%) |
| Previous EGFR-TKI treatment | |
| Yes | 29 (56%) |
| No | 23 (44%) |
| Previous antiangiogenic treatment | |
| Yes | 25 (48%) |
| No | 27 (52%) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, endothelial growth factor receptor; TKI, tyrosine kinase inhibitor.